Retrospective analysis showed sequential switching between onabotulinumtoxinA and erenumab improved outcomes in chronic migraine, indicating potential benefits in treatment plans.
Key Points
A very good response was noted in about 18% of patients who switched treatments for chronic migraine.
14 out of 78 patients experienced a very good response, defined as a 50% reduction in headache days.
Treatment with onabotulinumtoxinA and erenumab showed distinct but beneficial effects in chronic migraine management.
This study highlights the need for more data on the sequencing of migraine therapies for optimal patient outcomes.